Browse drugs

…r model.Results The expression constructs for pembrolizumab and nivolumab demonstrated dose-dependent expression in vitro. The PD-1/PD-L1…

…model MC-38. Through a late administration of either aCTLA-4 or aPD-1, we achieved partial vs complete responses in our model respect…

… cell activation, cytokine signaling, and antigen presentation. YM101 also reduced tumor proliferation and enhanced apoptosis, as sho…

…eoantigens were manufactured. Patients received weekly doses of TG4050 for 6 weeks followed by a maintenance period of one dose every …

… 32mos). We discover that after two cycles of chemotherapy with nivolumab long-term responders (PFS>12 months) have a tumor microenvironm…

… (ICI)-refractory MM (8 cutaneous, 5 mucosal, 4 uveal) received TILT-123 intravenously and intratumorally in a dose-escalating manner ac…

…d 97 heavy-light chain pairs through proteogenomic analysis.Our adalimumab anti-idiotype enrichment strategy yielded a polyclonal antibody…

…at the RP2D to preliminarily assess the anti-tumour activity of ANOC-001. Leukapheresis to collect autologous T-cell inputs for ANOC-001…

…n by metabolic stress, immunosuppression, and T cell exhaustion.IB-T101, an autologous CAR-T targeting CD70 in ccRCC, is expanded under…

…s (n=7, 47%), nivolumab/ipilimumab (n=3, 20%), atezolizumab and durvalumab (n=2 each, 13%), and cemiplimab and toripalimab (n=1 each, 7%) …

…ed 10 patients with PD-1-resistant advanced melanoma. Following H101 combined with anti-PD-1 treatment, tumor response assessment re…

…, regimen, safety, efficacy and long-term treatment outcomes of ATTR-01. Co-primary objectives are to characterise the safety and toler…